SEOUL - Genexine Inc. is to raise a total of KRW80bn ($69.3m) in bond and share issues to enable progression of global clinical trials for its core pipeline projects, including a promising HPV vaccine, and pursuing expanded indications.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?